Cargando…
The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review
BACKGROUND: Drug-resistant tuberculosis (DR-TB) has become a serious cause of concern both on a global scale and in South Africa. It is associated with a lower successful treatment rate, thus creating a hurdle in achieving good treatment outcomes for patients. AIM: The aim of this study was to compa...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AOSIS
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661289/ https://www.ncbi.nlm.nih.gov/pubmed/34917407 http://dx.doi.org/10.4102/hsag.v26i0.1708 |
_version_ | 1784613336072060928 |
---|---|
author | Singh, Lisa Mathibe, Lehlohonolo J. Bangalee, Varsha |
author_facet | Singh, Lisa Mathibe, Lehlohonolo J. Bangalee, Varsha |
author_sort | Singh, Lisa |
collection | PubMed |
description | BACKGROUND: Drug-resistant tuberculosis (DR-TB) has become a serious cause of concern both on a global scale and in South Africa. It is associated with a lower successful treatment rate, thus creating a hurdle in achieving good treatment outcomes for patients. AIM: The aim of this study was to compare the efficacy of the drug kanamycin, an injectable aminoglycoside, to bedaquiline, a newer oral drug used to treat DR-TB. METHODS: PubMed and Google Scholar, both of which are online databases, were extensively searched using the necessary keywords so that studies that were relevant to the scoping review were retrieved. A data-charting list was developed to extract the needed data for this scoping review. RESULTS: The main findings of the scoping review showed that bedaquiline was highly efficacious in the treatment of DR-TB, and that it was a valuable addition in the treatment of DR-TB. The findings of the study also showed that kanamycin does not have good efficacy against DR-TB. and its use extends the treatment of DR˗TB. CONCLUSION: It stands to reason that bedaquiline replaces kanamycin in the DR-TB drug regimen as it was shown to be more efficacious and patients experienced better treatment outcomes in a shorter period of time. There were also fewer adverse effects associated with bedaquiline as compared to kanamycin. CONTRIBUTION: Bedaquiline-based DR-TB therapy is more efficacious than aminoglycoside-based regimens which include kanamycin. |
format | Online Article Text |
id | pubmed-8661289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AOSIS |
record_format | MEDLINE/PubMed |
spelling | pubmed-86612892021-12-15 The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review Singh, Lisa Mathibe, Lehlohonolo J. Bangalee, Varsha Health SA Review Article BACKGROUND: Drug-resistant tuberculosis (DR-TB) has become a serious cause of concern both on a global scale and in South Africa. It is associated with a lower successful treatment rate, thus creating a hurdle in achieving good treatment outcomes for patients. AIM: The aim of this study was to compare the efficacy of the drug kanamycin, an injectable aminoglycoside, to bedaquiline, a newer oral drug used to treat DR-TB. METHODS: PubMed and Google Scholar, both of which are online databases, were extensively searched using the necessary keywords so that studies that were relevant to the scoping review were retrieved. A data-charting list was developed to extract the needed data for this scoping review. RESULTS: The main findings of the scoping review showed that bedaquiline was highly efficacious in the treatment of DR-TB, and that it was a valuable addition in the treatment of DR-TB. The findings of the study also showed that kanamycin does not have good efficacy against DR-TB. and its use extends the treatment of DR˗TB. CONCLUSION: It stands to reason that bedaquiline replaces kanamycin in the DR-TB drug regimen as it was shown to be more efficacious and patients experienced better treatment outcomes in a shorter period of time. There were also fewer adverse effects associated with bedaquiline as compared to kanamycin. CONTRIBUTION: Bedaquiline-based DR-TB therapy is more efficacious than aminoglycoside-based regimens which include kanamycin. AOSIS 2021-11-29 /pmc/articles/PMC8661289/ /pubmed/34917407 http://dx.doi.org/10.4102/hsag.v26i0.1708 Text en © 2021. The Authors https://creativecommons.org/licenses/by/4.0/Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License. |
spellingShingle | Review Article Singh, Lisa Mathibe, Lehlohonolo J. Bangalee, Varsha The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review |
title | The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review |
title_full | The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review |
title_fullStr | The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review |
title_full_unstemmed | The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review |
title_short | The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review |
title_sort | efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: a systematic scoping review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661289/ https://www.ncbi.nlm.nih.gov/pubmed/34917407 http://dx.doi.org/10.4102/hsag.v26i0.1708 |
work_keys_str_mv | AT singhlisa theefficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview AT mathibelehlohonoloj theefficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview AT bangaleevarsha theefficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview AT singhlisa efficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview AT mathibelehlohonoloj efficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview AT bangaleevarsha efficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview |